<DOC>
	<DOCNO>NCT02780830</DOCNO>
	<brief_summary>This modular study AZD2014 combination novel anti-cancer agent patient different subtypes relapse refractory Diffuse Large B-Cell Lymphoma ( DLBCL ) . Module 1 , combination ibrutinib patient non-germinal centre B-cell-like ( non-GCB ) DLBCL , consist Part A , Phase I dose-finding arm safety tolerability combination assess , Part B , Phase II dose-expansion phase ass efficacy combination .</brief_summary>
	<brief_title>AZD2014 Plus Novel Anti-Cancer Agents Relapsed Refractory Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>This modular , Phase I/IIa , open-label , multicentre study AZD2014 , administer orally , combination 2 novel anti-cancer agent , patient different subtypes relapse refractory DLBCL . Module 1 ass combination AZD2014 ibrutinib patient non-GCB DLBCL consist 2 part . Part A Phase I dose-finding study safety tolerability combination assess . Part B Phase IIa single-arm dose-expansion phase ass efficacy combination . Part A follow Continuous Reassessment Method ( CRM ) base Bayesian Adaptive Design identify AZD2014/ibrutinib dose combination incidence dose-limiting toxicity ( DLT ) less 33 % first cycle . It anticipate approximately 30 evaluable patient non-GCB DLBCL eligible stem cell transplant may enrol . The total number patient , however , depend upon number cohort necessary establish tolerate combination dose . Determination tolerate dos primarily base DLTs see Cycle 1 . Each cycle 28 day . Part A also include assessment single- multiple-dose pharmacokinetics combination AZD2014 ibrutinib . In Part B approximately 50 evaluable patient non-GCB DLBCL enrol . Patients receive AZD2014 ibrutinib dos establish Part A 28-day cycle unacceptable toxicity , disease progression , patient withdraws consent . Assessment response progressive disease occur Cycle 3 every 3 cycle first year , every 6 cycle ( 6 month ) thereafter . In Part B , predictive power monitoring use , could result stop Part B futility . An administrative interim analysis overall response rate conduct thereafter internal decision making , primary analysis conduct follow data analysis primary data cut-off date . The criterion success base confidence interval ( CI ) approach . Part B also include assessment impact repeat intermittent treatment AZD2014 MTD pharmacokinetics ( PK ) ibrutinib sub-group 9 patient ( Part B1 ) . The remain 41 patient ( Part B2 ) sparse PK sampling . In order eligible Module 1 participant must pathologically confirm DLBCL non-GCB subtype . Participants meet follow criterion may enrol Module 1 : 1 . Previous treatment Bruton 's tyrosine kinase ( BTK ) inhibitor and/or mammalian target rapamycin ( mTOR ) pathway inhibitor . 2 . History severe allergic anaphylactic reaction kinase inhibitor history hypersensitivity active inactive excipients ibrutinib drug similar chemical structure class ibrutinib . 3 . Recent infection require systemic treatment complete within 14 day prior first dose study drug .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Core Inclusion Criteria 1 . Males Females ( M/F ) ≥18 2 . Histopathologically confirm DLBCL 3 . Progressive Disease ( PD ) autologous stem cell transplantation ( ASCT ) ineligible ASCT 4 . Relapsed/refractory de novo disease , define : ) recurrence disease complete response ( CR ) , partial response ( PR ) , stable disease ( SD ) ; ii ) PD completion previous treatment regimen 5 . ≥1 lesion computerize tomography ( CT ) magnetic resonance imaging ( MRI ) &gt; 1.5 cm 6 . Adequate hematologic function 7 . Adequate hepatic renal function 8 . Prothrombin time ( PT ) /international normalise ratio ( INR ) &lt; 1.5 x upper limit normal ( ULN ) activate partial thromboplastin time &lt; 1.5 x ULN 9 . Serum potassium within normal limit ( WNL ) 10 . ECOG perf . status 0 1 11 . Female patient willing use 2 form contraception , breast feeding 12 . Male patient surgically sterile willing use effective barrier method contraception Core Exclusion Criteria 1 . Previous allogenic stem cell transplant . Patients may previous ASCT &gt; 3 month prior 2 . Prior standard antilymphoma therapy radiation therapy ≤ 14 day 3 . Concurrent systemic immunosuppressive therapy ≤ 28 day 4 . Major surgery &lt; 4 week minor surgery &lt; 14 day 5 . Haemopoeitic growth factor &lt; 7 day pegylated GCSF darbepoetin &lt; 14 day 6 . History severe allergic anaphylactic reaction kinase inhibitor hypersensitivity active inactive excipients vistusertib 7 . Live , attenuate vaccine &lt; 4 week 8 . Unresolved toxicity prior anticancer therapy exception alopecia . 9 . Bleeding disorder haemophilia 10 . History stroke intracranial haemorrhage &lt; 6 month 11 . Central nervous system ( CNS ) involvement lymphoma spinal cord compression 12 . Corticosteroid use exception control symptoms relate underlie disease and/or corticosteroid indication 20 mg/day prednisone 13 . History malignancies 14 . History HIV , active chronic hepatitis C , hepatitis B 15 . Have undergone following procedure experience condition currently &lt; 6 month : coronary artery bypass graft , angioplasty , vascular stent , myocardial infarction , angina pectoris , congestive heart failure [ New York Heart Association ( NYHA ) grade ≥ 2 ] , ventricular arrhythmia require continuous therapy , supraventricular arrhythmia , atrial fibrillation , haemorrhagic thrombotic stroke , TIA CNS bleeding . 16 . Abnormal echo/MUGA baseline 17 . Mean rest QTc &gt; 450 msec obtain 3 ECGs 18 . Factors increase risk QTc prolongation risk arrhythmic event heart failure , family history sudden unexplained death &lt; 40 yearsofage 19 . Type I uncontrolled Type 2 diabetes mellitus . 20 . Clinically significant preexist renal disease high risk develop renal impairment . 21 . Refractory nausea vomiting , malabsorption syndrome , disease significantly affect GI function , resection stomach small bowel , symptomatic inflammatory bowel disease ulcerative colitis , partial complete bowel obstruction . 22 . Concomitant use therapeutic anticoagulant exception shortacting heparin 23 . Exposure potent moderate inhibitor inducer CYP 3A4/5 , multi drug resistance 1 ( MDR1 ) permeability glycoprotein ( Pgp ) , breast cancer resistance protein ( BCRP ) 24 . Exposure sensitive narrow therapeutic range substrate drug metabolise enzyme CYP2C8 , CYP2C9 , CYP2C19 , CYP2D6 drug transporter Pgp ( MDR1 ) , BCRP , OATP1B1 , OATP1B3 , OCT1 OCT2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>non-GCB Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Relapsed Refractory non-GCB Diffuse Large B-Cell Lymphoma</keyword>
	<keyword>Vistusertib</keyword>
	<keyword>AZD2014</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Imbruvica</keyword>
</DOC>